Hepatocellular carcinoma in Ghana: a retrospective analysis of a tertiary hospital data

Hepatocellular carcinoma in Ghana: a retrospective analysis of a tertiary hospital data

Kenneth Tachi^1,&, Adwoa Agyei-Nkansah¹, Timothy Archampong¹

¹Department of Medicine, Medical School, College of Health Sciences, University of Ghana, Accra, Ghana

^&Corresponding author
Kenneth Tachi, Department of Medicine, Medical School, College of Health Sciences, University of Ghana, Accra, Ghana

Introduction    

Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world, but its very poor prognosis makes it the third leading cause of cancer-related mortality worldwide [1]. Its epidemiology varies by region in parallel with prevalence of the major risk factors; chronic HBV and hepatitis C virus (HCV) infections [2]. More than 80% of HCC occur in developing economies, with Asian and sub-Saharan African (SSA) countries being the most afflicted [1]. In Asia and SSA, HBV is the most common risk factor for HCC, while HCV is the most common risk factor for HCC in North America, Europe, Japan and Egypt [1-3]. Ghana is a SSA country with a high prevalence of chronic HBV, estimated at 12.9% [4]. HCV is not uncommon at a prevalence of 3% [5]. The incidence and mortality rates of HCC in Ghana are estimated at 17.6 and 17.1 per 100,000 respectively [6]. HCC was also reported as first and third leading causes of cancer deaths in men and women respectively between 1991 and 2000 in Ghana [7]. Data on several other aspects of HCC is however lacking, resulting in a poor appreciation of the high burden of the disease and the impact of chronic viral hepatitis on the population. The aim of this study therefore was to comprehensively describe the clinical, laboratory and radiological features of HCC at the Korle Bu Teaching Hospital in Ghana.

Methods     

This study used a retrospective design to evaluate cases of HCC who attended the Gastrointestinal (GI) Clinic of the Korle Bu Teaching Hospital in Accra, Ghana between January 2015 and December 2018. The Korle Bu Teaching Hospital (KBTH) is a tertiary hospital with about 1,700 bed capacity. It receives referrals mostly from the southern sector of Ghana. The study was approved by the Ethical and Protocol Review Committee of the College of Health Science, University of Ghana (I.D: CHS-Et/M.7 -4.1/2018-2019). Permission to access the patients´ medical records was obtained from the medical records unit of the hospital but no informed consent was obtained because of the retrospective nature of the study. The diagnosis of HCC was based on any one of the following; histopathological confirmation of HCC, presence of a liver mass with characteristic HCC imaging changes on computed tomography (CT) or magnetic resonance imaging (MRI), alpha-fetoprotein (AFP) levels >165.2 IU/ML and liver mass on ultrasonography (USG) or clinical context (weight loss, hard nodular hepatomegaly or presence of a chronic liver disease or cirrhosis) positive serological markers of HBV or HCV infections and alpha-fetoprotein (AFP) levels >165.2 IU/ML [8, 9]. The following cases were excluded; medical records with incomplete data to confirm a diagnosis of HCC, persons less than 13 years as the GI Clinic only sees patients above 13 years and cases in which liver metastasis could not be excluded conclusively after review of the records. The following information was gathered from the medical records of patients meeting the inclusion criteria; demographic data, presenting symptoms, knowledge of and medical care for HBV status prior to diagnosis, laboratory results (HBsAg, Anti-HCV, HIV, LFT, FBC, AFP), results of various imaging modalities, liver histology if done, and treatment received. The data was anonymized and safely stored on a computer. Descriptive statistics was used for analysis of patients´ demographic information and other categorical variables. Measured outcomes were analyzed as mean±standard deviation. These were presented as tables. Associations and differences in categorical outcome variables were determined by the Chi-square test, while grouped sample t-test or the one-way analysis of variance (ANOVA) was used for continuous outcome measures at 95% confidence interval.

Results     

A total of 194 cases of HCC met the inclusion criteria and data extracted for analysis. There were 129 males and 65 females giving a male:female ratio of 2:1. The age of the cases ranged from 16-85 years with mean age of 45.2 years. The mean ages of males and females were 43.3 and 48.9 years respectively. Other demographic features of the cases are shown in Table 1; 136 (71.6%) of 190 were married, 39.2% admitted to alcohol intake and 6.7% to smoking. Fifty-two (43.3%) males and 15 (29.4%) females admitted to alcohol use whiles 9 (7.6%) males and 2 (4.4%) females admitted to smoking. Weight loss (77.1%) and abdominal pain (73.1%) were the major presenting symptoms. The other presenting symptoms are also shown in Table 1. HBV was the leading aetiological factor associated with HCC. HBsAg was positive in 104/145 (71.7%) of cases tested whiles 8 (8.5%) out of 94 and 2 (7.4%) out of 27 cases tested positive for HCV and HIV respectively. No patient had infection with more than 1 virus. HBsAg test was positive in 76.8% of males and 72.0% of females. There was significant association between HBsAg status and the age groups but no other demographic or clinical parameters (Table 1).

Sixty-five (62.5%) of 104 HBsAg positives were aware of their HBsAg status prior to the diagnosis of HCC. However, only 3 were receiving medical follow up and 2 were on treatment for HBV. The mean age for HBsAg positive HCC was less than for HCV and HIV; 41.7 years for HBV, 55.1 years for HCV, 43.5 years for HIV. The mean ages for HBsAg positives with concomitant alcohol use or smoking were 42.5 and 44.8 years respectively. The small numbers of HCV and HIV cases prevented evaluation of similar effect of alcohol on these viruses. The major laboratory test abnormality was AST elevations (76.2%) and low total protein (5.4%) the least frequent occurrence (Table 2). The alpha fetoprotein (AFP) results were recorded for only 141 patients and was abnormal (>10 IU/ML) in 81.6%. The AFP levels ranged from 0.54 to 750000 IU/ML with a mean AFP of 12866 IU/ML. More than half of the patients (52%) had AFP >165.3 IU/ML, the set cut off. The AFP and haemoglobin levels were significantly associated with HBsAg status (p = 0.040 and 0.012 respectively). One hundred and thirty-eight (138) of the 194 patients, had documented abdominal ultrasound examination and 50 abdominal CT scans but none had abdominal MRI. Liver histology was documented in 3 patients only. On abdominal ultrasound imaging, 15 (7.7%) had background cirrhosis, 44 (22.7%) presented with single liver mass, 78 (40.2%) with multiple liver masses and 41 (21.1%) with ascites. Analgesia was the first and only treatment prescribed to 144 of the patients and 4 patients were on sorafenib. One patient underwent microwave ablation. No patients in the cohort had undergone liver resection or transplant, or transarterial chemoembolization.

Discussion     

In this study, we have reported for the first time the demographic, clinical, laboratory and radiological characteristics of HCC from the KBTH, in Ghana. The demographic characteristics of HCC cases at KBTH appear to confirm previously known trends about the disease in Ghana and the West African Region. The male predominance seen in this report has been previously reported in Ghana, West Africa and globally [10-12]. This has previously been attributed to the higher prevalence of risk factors including chronic viral hepatitis, environmental carcinogens like alcohol and smoking, higher testosterone levels and lower levels of IL-6 production in males [13, 14]. Indeed in this study, higher prevalence of alcohol use and smoking was found in males than females. The relative importance of hepatitis to HCC causation varies greatly worldwide. This study confirms the important contribution of HBV to HCC in Ghana as in many other SSA countries [2, 12]. HBsAg positivity of 71.7% is higher than 52% previously reported in 2015 from Kumasi in Ghana and 60% from The Gambia and 48% from Ethiopia, both of which also have very high population prevalence of HBV [9, 11, 15]. The positive aspect to this finding is that HCC in Ghana remains a largely preventable cancer if the appropriate HBV control measures like childhood vaccination as in Taiwan and access to antiviral therapy can be effectively implemented [16, 17]. This study also highlights the unfortunate poor health seeking behavior of the cohort and possibly the Ghanaian population in general. Whilst almost two-thirds of the HBsAg positive had prior knowledge of their positive HBsAg status, their medical follow up and treatment for same was poor. This is likely attributable to the largely asymptomatic nature of chronic HBV infections until late, when complications set in. Other reasons could include seeking help from faith based care providers for reasons such as cost, greater satisfaction with care provided by these faith based healers [18]. Beyond screening to identify the infected population, vigorous education will be required to change this behaviour.

Hepatocellular carcinoma attributable to HBV from this study occurred at a relatively younger age than those attributable to HCV. This is similar to what has been reported from other HBV endemic regions of the world [3, 12, 19]. The reasons for this observation include the early age of infection with HBV in these regions. It is however surprising that alcohol use did not impact on the age of presentation of HCC especially as a synergistic effect of alcohol and HBV on HCC causation in some West African countries has been reported [20]. Umoh et al. however had earlier found alcohol to have only a minor role as a risk factor among HCC patients in The Gambia [9]. More work is needed to define the factors that drive the synergism between alcohol and HBV to cause HCC. The typical HCC patient from this study presented with abdominal pain and/or weight loss. This is very similar to a previous report among HCC patients in the Gambia and South Africa [9, 21]. The lack of patients identified through surveillance, the recommended way to diagnosing early HCC is consistent with global trends of underutilization of surveillance for early detection of HCC [22]. Factors that have been shown to affect utilization of surveillance include clinician knowledge and level of training as well as patient factors like myths that healthy diet and lack of symptoms are protective against HCC [23-25]. This study however did not assess the reasons for our findings. Abnormal AFP proportion reported in this study is similar to that reported (60-80%) in literature [26, 27]. The optimal cut off and use of AFP in diagnosis however remains controversial. At least in Asian patients with suspicious liver lesions, the cut-off AFP level of 200 ng/ml (165.2 IU/ML) is reported as useful to achieve a diagnosis of HCC with high specificity and reasonable sensitivity [8, 26]. More than 50% of patients in this study had AFP levels beyond this cut off. Despite its many limitations as a diagnostic tumour marker, it is difficult to discount AFP as a useful tool in resource poor economies like Ghana. More work is needed to establish appropriate cut off and acceptable sensitivity and specificity for diagnosis. The imaging modality for diagnosis of HCC in this study was limited to USG imaging in the majority of cases even though it is inferior to CT and MRI and recommended only as a cost effective screening tool by guidelines [8, 28-30]. The low use of these recommended multiphase imaging techniques is likely due to cost or non-availability. It is important that as a first step, ultra sonographers are properly trained to identify and characterize liver masses whiles efforts are made to improve the availability CT scans and MRIs. The proportion of patients in many African countries receiving specific HCC treatment has been disappointingly low compared to the trend in Asia, Europe and North America [12, 31]. Gyedu et al. have also previously reported that HCC patients in Ghana were not eligible for surgical resection [11]. This study similarly finds low utilization of potentially curative therapies of HCC like resection, radiofrequency ablation and percutaneous ethanol injection. The reasons as from previous reports are likely due to late presentation and with advanced diseases not amenable to these therapies, non-availability of these treatment modalities and the high cost of these treatments even when available. There is therefore a need to improve efforts aimed at early diagnosis and access to specific HCC treatment. This will require commitment from policy makers.

Limitations

This was a retrospective review of medical records and therefore some aspects of the data collected were incomplete. This had the potential to create bias in the analysis and interpretation. Additionally, vital information like HBeAg status and HBV DNA levels were unavailable for majority of the patients. Also, KBTH is a referral centre, and so data from here may not be representative of the HCC burden and characteristics in other facilities across the country. Finally, it is likely that some cases that were referred to other specialists for other modalities of treatment like resection, microwave ablation and TACE, did not return to the unit and so their records were unavailable for analysis.

Conclusion     

HCC presenting to KBTH affects more males than females. Hepatitis B virus infection is the leading aetiologial risk factor associated with HCC. Most HBV infected patients were aware of their infection status but were not receiving medical care and/or treatment for HBV prior to HCC diagnosis. No patients were identified through surveillance. Presentations with the major symptoms of weight loss and abdominal pain qualifies most patients for only supportive rather than curative HCC treatment at KBTH. There is an urgent need to improve education of the population on hepatitis and its dreaded complication HCC. Health care providers should also be provided with HCC surveillance education and should establish programmes to implement same. Finally, policy makers should invest resources to improve diagnosis and treatment. If these are done, only then can we hope to identify early disease and offer specific or curative treatment to HCC patients.

Competing interests     

The authors declare no competing interests.

Authors' contributions     

Dr. Kenneth Tachi contributed substantially to conception and design, acquisition of data, analysis and interpretation of data, drafting and revising manuscript, approval of final manuscript and submission for publication. Dr. Adwoa Agei-Nkansah and Dr. Timothy Archeampong contributed to design, acquisition of data, interpretation of data, editing of the draft and approval of final manuscript for publication. All authors read and approved the final version of the manuscript.

Acknowledgments     

We are grateful to Mr. Abiola Sefiu Alao and Miss Omaima Mohammed Arab of the University of Ghana Medical School for their assistance with data collection. We are also grateful to Mr. John Tetteh for his immense support with the data analysis.

Tables     

Table 1: demographic, clinical and laboratory characteristics of hepatocellular patients according to HBsAg status

Table 2: laboratory test results among hepatocellular patients

References     

1. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017 Apr 1;3(4):524-548. PubMed | Google Scholar


2. Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. International journal of cancer. 2018 Jun 15;142(12):2471-7. Epub 2018/02/0 eng. PubMed | Google Scholar


3. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012 May;142(6):1264-73. Epub 2012/04/28. PubMed | Google Scholar


4. Ofori-Asenso R, Agyeman AA. Hepatitis B in Ghana: a systematic review & meta-analysis of prevalence studies (1995-2015). BMC infectious diseases. 2016 Mar 18;16:130. Epub 2016/03/19. eng. PubMed | Google Scholar


5. Agyeman AA, Ofori-Asenso R, Mprah A, Ashiagbor G. Epidemiology of hepatitis C virus in Ghana: a systematic review and meta-analysis. BMC infectious diseases. 2016 Aug 9;16:391. Epub 2016/08/11. PubMed | Google Scholar


6. Ladep NG, Lesi OA, Mark P, Lemoine M, Onyekwere C, Afihene M et al. Problem of hepatocellular carcinoma in West Africa. World journal of hepatology. 2014 Nov 27;6(11):783-92. Epub 2014/11/28. PubMed | Google Scholar


7. Wiredu EK, Armah HB. Cancer mortality patterns in Ghana: a 10-year review of autopsies and hospital mortality. BMC public health. 2006 Jun 20;6:159. Epub 2006/06/22. PubMed | Google Scholar


8. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology international. 2017 Jul;11(4):317-70. Epub 2017/06/1. PubMed | Google Scholar


9. Umoh NJ, Lesi OA, Mendy M, Bah E, Akano A, Whittle H et al. Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia. Liver international: official journal of the International Association for the Study of the Liver. 2011 Feb;31(2):215-21. Epub 2010/12/15. PubMed | Google Scholar


10. Rawla P, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. Contemporary oncology (Poznan, Poland). 2018;22(3):141-50. Epub 2018/11/21. PubMed | Google Scholar


11. Gyedu A, Shrauner WR, Kingham TP. No patients to resect or transplant: an analysis of patients with hepatocellular carcinoma admitted to a major African referral hospital. World journal of surgery. 2015 Jan;39(1):231-6. Epub 2014/08/30. PubMed | Google Scholar


12. Yang JD, Gyedu A, Afihene MY, Duduyemi BM, Micah E, Kingham TP et al. Hepatocellular Carcinoma Occurs at an Earlier Age in Africans, Particularly in Association With Chronic Hepatitis B. The American journal of gastroenterology. 2015 Nov;110(11):1629-31. Epub 2015/12/01. PubMed | Google Scholar


13. Tognarelli J, Ladep NG, Crossey MM, Okeke E, Duguru M, Banwat E et al. Reasons why West Africa continues to be a hotbed for hepatocellular carcinoma. Nigerian medical journal: journal of the Nigeria Medical Association. 2015 Jul-Aug;56(4):231-5. Epub 2016/01/14. PubMed | Google Scholar


14. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (New York, NY). 2007 Jul 6;317(5834):121-4. Epub 2007/07/07. PubMed | Google Scholar


15. Mekonnen HD, Sharma S, Shewaye A, Feld J, Lulu E. Major Risk Factors, Clinical And Laboratory Characteristics Of Patients With Hepatocellular Carcinoma; A Retrospective Study At Tikur Anbassa Hospital, Addis Ababa University, Addis Ababa, Ethiopia. Ethiopian medical journal. 2015 Jul;53(3):127-32. PubMed PMID: 26677522. Epub 2015/12/19. eng. PubMed | Google Scholar


16. Hung GY, Horng JL, Yen HJ, Lee CY, Lin LY. Changing incidence patterns of hepatocellular carcinoma among age groups in Taiwan. Journal of hepatology. 2015 Dec;63(6):1390-6. Epub 2015/08/11. PubMed | Google Scholar


17. Shih C, Chou SF, Yang CC, Huang JY, Choijilsuren G, Jhou RS. Control and Eradication Strategies of Hepatitis B Virus. Trends in microbiology. 2016 Sep;24(9):739-49. Epub 2016/06/12. PubMed | Google Scholar


18. Olivier J, Tsimpo C, Gemignani R, Shojo M, Coulombe H, Dimmock F et al. Understanding the roles of faith-based health-care providers in Africa: review of the evidence with a focus on magnitude, reach, cost, and satisfaction. Lancet (London, England). 2015 Oct 31;386(10005):1765-75. PubMed PMID: 26159398. Epub 2015/07/15. eng. PubMed | Google Scholar


19. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nature reviews Gastroenterology & hepatology. 2010 Aug;7(8):448-58. PubMed PMID: 20628345. Epub 2010/07/16. PubMed | Google Scholar


20. Jaquet A, Tchounga B, Tanon A, Bagny A, Ekouevi DK, Traore HA et al. Etiology of hepatocellular carcinoma in West Africa, a case-control study. International journal of cancer. 2018 Aug 15;143(4):869-77. PubMed PMID: 29569722. Pubmed Central PMCID: PMC6041181. Epub 2018/03/24. eng. PubMed | Google Scholar


21. Kew MC. Hepatocellular carcinoma with and without cirrhosis. A comparison in southern African blacks. Gastroenterology. 1989 Jul;97(1):136-9. Epub 1989/07/01. PubMed | Google Scholar


22. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nature reviews Gastroenterology & hepatology. 2019 Oct;16(10):589-604. Epub 2019/08/24. PubMed | Google Scholar


23. Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Annals of internal medicine. 2011 Jan 18;154(2):85-93. Epub 2011/01/19. PubMed | Google Scholar


24. Goldberg DS, Taddei TH, Serper M, Mehta R, Dieperink E, Aytaman A et al. Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. Hepatology (Baltimore, Md). 2017 Mar;65(3):864-74. Epub 2016/08/18. PubMed | Google Scholar


25. Farvardin S, Patel J, Khambaty M, Yerokun OA, Mok H, Tiro JA et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology (Baltimore, Md). 2017 Mar;65(3):875-84. Epub 2016/08/18. PubMed | Google Scholar


26. Chan SL, Mo F, Johnson PJ, Siu DY, Chan MH, Lau WY et al. Performance of serum alpha-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2014 Apr;16(4):366-72. Epub 2013/08/29. eng. PubMed | Google Scholar


27. Chan SL, Chan AT, Yeo W. Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both? Future oncology (London, England). 2009 Aug;5(6):889-99. Epub 2009/08/12. PubMed | Google Scholar


28. European Association for the Study of the Liver, Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F et al. Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of hepatology. 2018 Jul;69(1):182-236. Epub 2018/04/10. PubMed | Google Scholar


29. Snowberger N, Chinnakotla S, Lepe RM, Peattie J, Goldstein R, Klintmalm GB et al. Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Alimentary pharmacology & therapeutics. 2007 Nov 1;26(9):1187-94. PubMed PMID: 17944733. Epub 2007/10/20. eng. PubMed | Google Scholar


30. Ronot M, Pommier R, Dioguardi Burgio M, Purcell Y, Nahon P, Vilgrain V. Hepatocellular carcinoma surveillance with ultrasound-cost-effectiveness, high-risk populations, uptake. The British journal of radiology. 2018 Oct;91(1090):20170436. PubMed PMID: 29446324. Epub 2018/02/16. PubMed | Google Scholar


31. Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver international: official journal of the International Association for the Study of the Liver. 2015 Sep;35(9):2155-66. Epub 2015/03/11. PubMed | Google Scholar